The Indian Journal of Dermatology, Venereology and Leprology (IJDVL) is a bimonthly publication of the Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) and is published for IADVL by Medknow Publications.

The Journal is indexed listed with Science Citation Index Expanded, PUBMED, EMBASE, Bioline International, CABI Abstracts, Global Health, DOAJ, Health and Wellness Research Center, SCOPUS, Health Reference Center Academic, InfoTrac One File, Expanded Academic ASAP, NIWI, INIST, Uncover, JADE (Journal Article Database), IndMed, Indian Science Abstract’s and PubList.

All the rights are reserved. Apart from any fair dealing for the purposes of research or private study, or criticism or review, no part of the publication can be reproduced, stored, or transmitted, in any form or by any means, without the prior permission of the Editor, IJDVL.

The information and opinions presented in the Journal reflect the views of the authors and not of the IADVL or its Editorial Board or the IADVL. Publication does not constitute endorsement by the journal.

The IJDVL and/or its publisher cannot be held responsible for errors or for any consequences arising from the use of the information contained in this journal.

The journal is published and distributed by Medknow Publications. Copies are sent to subscribers directly from the publisher’s address. It is illegal to acquire copies from any other source. If a copy is received for personal use as a member of the association/society, one can not resale or give-away the copy for commercial or library use.

The Journal is printed on acid free paper.
EDITORIAL REPORT - 2007

IJDVL gets into the Science Citation Index Expanded!
Uday Khopkar ............................................................................................................................................................... 1

EDITORIAL

Registration and reporting of clinical trials
Uday Khopkar, Sushil Pande ....................................................................................................................................... 2

SPECIALTY INTERFACE

Preventing steroid induced osteoporosis
Jyotsna Oak................................................................................................................................................................... 5

REVIEW ARTICLE

Molecular diagnostics in genodermatoses - simplified
Ravi N. Hiremagalore, Nagendra Chary Nizamabad, Vijayaraghavan Kamasamudram ............................................... 8

ORIGINAL ARTICLES

A clinicoepidemiological study of polymorphic light eruption
Lata Sharma, A. Basnet ................................................................................................................................................ 15

A clinico-epidemiological study of PLE was done for a period of one year to include 220 cases of PLE of skin type between IV and VI. The manifestation of PLE was most common in housewives on sun exposed areas. Most of the patients of PLE presented with mild symptoms and rash around neck, lower forearms and arms which was aggravated on exposure to sunlight. PLE was more prevalent in the months of March and September and the disease was recurrent in 31.36% of cases.

Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: A randomized, double-blind, multicentric study
Anil Pareek, Uday Khopkar, S. Sacchidanand, Nitin Chandurkar, Geeta S. Naik ................................................... 18

In a double-blind randomized, comparative multicentric study evaluating efficacy of antimalarials in polymorphic light eruption, a total of 117 patients of PLE were randomized to receive hydroxychloroquine and chloroquine tablets for a period of 2 months (initial twice daily dose was reduced to once daily after 1 month). A significant reduction in severity scores for burning, itching, and erythema was observed in patients treated with hydroxychloroquine as compared to chloroquine. Hydroxychloroquine was found to be a safe antimalarial in the dosage studied with lesser risk of ocular toxicity.
Many faces of cutaneous leishmaniasis
Arfan Ul Bari, Simeen Ber Rahman

Symptomatic cutaneous leishmaniasis is diverse in its presentation and outcome in a tropical country like Pakistan where the disease is endemic. The study describes the clinical profile and atypical presentations in 41 cases among 718 patients of cutaneous leishmaniasis. Extremity was the most common site of involvement and lupoid cutaneous leishmaniasis was the most common atypical form observed. Authors suggest that clustering of atypical cases in a geographically restricted region could possibly be due to emergence of a new parasite strain.

Forehead plaque: A cutaneous marker of CNS involvement in tuberous sclerosis
G. Raghu Rama Rao, P. V. Krishna Rao, K. V. T. Gopal, Y. Hari Kishan Kumar, B. V. Ramachandra

In a retrospective study of 15 patients of tuberous sclerosis, eight patients had central nervous system involvement. Among these 8 cases, 7 cases had forehead plaque. This small study suggests that presence of forehead plaque is significantly associated with CNS involvement.

BRIEF REPORTS

Ligand-binding prediction for ErbB2, a key molecule in the pathogenesis of leprosy
Viroj Wiwanitkit

SCORTEN: Does it need modification?
Col. S. S. Vaishampayan, Col. A. L. Das, Col. R. Verma

CASE REPORTS

Universal acquired melanosis (Carbon baby)
P. K. Kaviarasan, P. V. S. Prasad, J. M. Joe, N. Nandana, P. Viswanathan

Adult onset, hypopigmented solitary mastocytoma:
Report of two cases
D. Pandhi, A. Singal, S. Aggarwal
Incidental finding of skin deposits of corticosteroids without associated granulomatous inflammation: Report of three cases
Rajiv Joshi ..................................................................................................................................................................... 44

Erythromelanosis follicularis faciei et colli: Relationship with keratosis pilaris
M. Augustine, E. Jayaseelan ........................................................................................................................................ 47

Naxos disease: A rare occurrence of cardiomyopathy with woolly hair and palmoplantar keratoderma
R. Rai, B. Ramachandran, V. S. Sundaram, G. Rajendren, C. R. Srinivas ................................................................. 50

Granular parakeratosis presenting with facial keratotic papules
R. Joshi, A. Taneja ......................................................................................................................................................... 53

LETTERS TO THE EDITOR

Extragenital lichen sclerosus of childhood presenting as erythematous patches
N. G. Stavrianeas, A. C. Katoulis, A. I. Kanelleas, E. Bozi, E. Toumbis-Ioannou ..................................................... 59

Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection
Esra Adisen, Murat Dizbay, Kenan Hize, Nilsel İlter ........................................................................................................ 60
Poland’s syndrome
Saurabh Agarwal, Ajay Arya

Hereditary leiomyomatosis with renal cell carcinoma
Sachin S. Soni, Swarnalata Gowrishankar, Gopal Kishan Adikey, Anuradha S. Raman

Infantile onset of Cockayne syndrome in two siblings
Prerna Batra, Abhijeet Saha, Ashok Kumar

Multiple xanthogranulomas in an adult
Surajit Nayak, Basanti Acharjya, Basanti Devi, Manoj Kumar Patra

Bullous pyoderma gangrenosum associated with ulcerative colitis
Naik Chandra Lal, Singh Gurcharan, Kumar Lekshman, Lokanatha K

Sporotrichoid pattern of malignant melanoma
Ranjan C. Rawal, Kanu Mangla

Acitretin for Papillon-Lefèvre syndrome in a five-year-old girl
Didem Didar Balci, Gamze Serarslan, Ozlem Sangun, Seydo Homan

Bilateral Becker’s nevi
Ramesh Bansal, Rajeev Sen

Madarosis: A dermatological marker
Silonie Sachdeva, Pawan Prasher
FOCUS

Botulinum toxin
Preeti Savardekar ......................................................................................................................................................... 77

E-IJDVL

Net Studies
A study of oxidative stress in paucibacillary and multibacillary leprosy
P. Jyothi, Najeeba Riyaz, G. Nandakumar, M. P. Binitha .......................................................................................... 80
Clinical study of cutaneous drug eruptions in 200 patients
M. Patel Raksha, Y. S. Marfatia.................................................................................................................................... 80
Net case
Porokeratosis confined to the genital area: A report of three cases
Sujata Sengupta, Jayanta Kumar Das, Asok Gangopadhyay ................................................................................... 80
Net Letters
Camisa disease: A rare variant of Vohwinkel’s syndrome
T. S. Rajashekar, Gurcharan Singh, Chandra Naik, L. Rajendra Okade ................................................................... 81
Cross reaction between two azoles used for different indications
Arika Bansal, Rashmi Kumari, M. Ramam ................................................................................................................. 81
Net Quiz
Asymptomatic erythematosus plaque on eyelid
Neeraj Srivastava, Lakhan Singh Solanki, Sanjay Singh .......................................................................................... 82

QUIZ

A bluish nodule on the arm
Ragunatha S., Arun C. Inamadar, Vamseedhar Annam, B. R. Yelikar ..................................................................... 83

REFEREE INDEX-2007

INSTRUCTIONS FOR AUTHORS

The copies of the journal to members of the association are sent by ordinary post. The editorial board, association or publisher will not be responsible for non-receipt of copies. If any of the members wish to receive the copies by registered post or courier, kindly contact the journal’s / publisher’s office. If a copy returns due to incomplete, incorrect or changed address of a member on two consecutive occasions, the names of such members will be deleted from the mailing list of the journal. Providing complete, correct and up-to-date address is the responsibility of the members. Copies are sent to subscribers and members directly from the publisher’s address; it is illegal to acquire copies from any other source. If a copy is received for personal use as a member of the association/society, one cannot resale or give-away the copy for commercial or library use.
Clinical trials form an integral part of the drug discovery process worldwide. However, registration of clinical trials is not restricted to drug interventions. A clinical trial is defined as “any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.” Interventions include not only drugs but also cells and other biological products, surgical procedures, radiologic procedures, devices, behavioral treatments, process-of-care changes, preventive care, etc. A set of guidelines are already in place in India for the ethical conduct of studies to safeguard the interests of patients or volunteers participating in the study. However, there is a need to promote knowledge and awareness of regulatory laws and the more recent phenomenon of registration of clinical trials in India.

INADEQUATE AND SELECTIVE REPORTING

Currently, apart from a few academic clinical trials sponsored by government bodies or NGOs, the majority of clinical trials conducted in India are sponsored, randomized controlled trials. Most of the major hospitals are equipped with appropriately constituted Institutional Ethics Committees (IEC) and Review Boards (IRB). However, the results of clinical trials or their information are not adequately disseminated in many instances. Only selected or positive results might get published which are at risk of being doubted as being biased. Often in such cases, valuable scientific efforts are wasted without yielding desired outcomes. As reports of clinical trials form an important source of information for practitioners, researchers, academicians and the public, it is the moral, ethical and scientific responsibility of researchers to report the results. The so called ‘discreetness’ of clinical trials defeats the very purpose of scientific research and principles of evidence-based medicine. It may distort the evidence required for making correct clinical decisions. Besides, it deprives trial participants, the general public and fellow researchers of their right to information. It commonly results in duplication of efforts and wastage of vital resources.

CLINICAL TRIAL REGISTRATION

In order to make clinical data and reports available to all, an online clinical registry has been initiated by the Indian Council of Medical Research (ICMR) for the registration of any interventional trial to ensure the following goals:
1. Transparency and accountability of clinical research
2. Internal validity of clinical trials
3. To oversee the ethical conduct of clinical trials
4. Reporting of results of clinical trials

The clinical trial registry of India (CTRI) is the online registry of prospective clinical trials in India. This is the initiative started by the National Institute of Medical Statistics (NIMS) of the Indian Council of Medical Research and is supported by the Department of Science and Technology (DST) and the World Health Organization (WHO).

CTRI will create a database of prospective clinical trials in India after their registration. The data and reports of these clinical trials and their status will be available to the public and professionals free of cost after formal registration on their website www.ctri.in Currently, the registration of clinical trials is only voluntary and not mandatory. With increased
awareness about this initiative and wide acceptance of the purpose of CT registration, it is likely that it may become mandatory in the future for initiation of clinical trials in India.

It has been affirmed that CT registration should be done before the actual enrollment of study subjects in the trial. The principal investigator or sponsor should share the responsibility of CT registration. In the case of multicentric studies, the lead investigator or sponsor should ensure that the CT is registered.

For the registration of a CT, it is essential to declare 20 items relevant to the CT as determined by the International Clinical Trial Registration Platform (ICTRP) of the World Health Organization (ICRTP-WHO). For registration with the CTRI, additional items related to the EC or IRB’s permission and that of Director Controller General of India (DCGI) are included. At the end of a successful registration, each CT is assigned a unique WHO identification number called the Unique Trial Reference Number (UTRN) [Table 1].

**REGISTRATION OF NONSPONSORED CLINICAL TRIALS**

It is widely perceived that the registration requirement for clinical trials refers only to sponsored trials. However, current guidelines for the registration of clinical trials do not make any distinction between sponsored and nonsponsored trials. Enforcement of registration for nonsponsored studies also offers the same advantages as for sponsored trials. Hence, as of today, it is recommended that all clinical trials, sponsored or nonsponsored, be registered at the time of inception. This includes a large number of interventional clinical studies that are conducted in medical colleges as part of postgraduate dissertations. It is particularly important for these to be registered as many of these are duplicated studies and not reporting them leads to wastage of resources.

**PUBLICATION OF CLINICAL TRIALS**

Although the CTRI is a recent phenomenon, similar registries have been in existence in other countries for some time. As such pretrial registration ensures the authenticity of a clinical trial, medical journal editors prefer a registered clinical trial over an unregistered one. Therefore, registration before the initiation of a trial is a prerequisite for publishing clinical trial data in many medical journals.

**Table 1: Registration parameters for Indian registry**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Required</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>UTRN*</td>
<td>Mandatory</td>
<td></td>
</tr>
<tr>
<td>Registration Number</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trial Registration Date</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public title of study*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scientific Title of Study (Give Trial Acronym, if any)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary IDs, if any</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Principal Investigator’s Name and Address</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Person (Scientific Query)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Person (Public Query)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding Source/s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary Sponsor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary Sponsor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name of Ethics Committee and approval status*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulatory Clearance obtained from DCGI*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of first enrollment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated duration of trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target sample size</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Condition/Problem studied</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervention and Comparator agent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key inclusion/Exclusion Criteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary Outcome/s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary Outcome/s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Countries of Recruitment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site/s of study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Status of Trial*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase of Trial*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brief Summary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method of generating randomization sequence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Method of allocation concealment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding and masking</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Items that are mandatory; bold text indicates additional items required by the ICMR for Indian trials

Member journals of the International Committee of Medical Journal Editors (ICMJE) declared in a common editorial published in 2004, that their journals will not publish the results of any clinical trial that began recruitment after 1st July 2005 if it was not registered with an authorized registry at the time of inception of the trial.\[3\] Studies on pharmacokinetics or major toxicity (e.g., phase I trials) have been exempted by ICMJE guidelines to ensure protection of original ideas.\[4\] However, it is mandatory for all the pharma sponsors to make public all their findings within a given framework of time as a part of their responsibility to the public at large.

Thus, clinical trial registration offers unique advantages to researchers in terms of the smooth publication of results.
in international and national journals. Apart from this, it encourages researchers to engage in more meaningful and scientifically and ethically sound clinical research. Needless to say, it will build up public confidence in the conduct and authenticity of clinical trials.

Currently, most Indian journals do not enforce the registration for clinical trial reports that are submitted to them for publication. However, with the recent launch of the CTRI website, it may soon become inevitable for them to enforce the registration at the time of inception of a study.

REFERENCES


Multiple Choice Questions

1. Alternative forms of a particular DNA sequence or a gene is called
   a. Polymorphism, b. Allele, c. Locus, d. Genotype

2. Allelic heterogeneity refers to
   a. Mutations in the same gene causing different clinical entities, b. Mutations in different genes causing same clinical phenotype, c. Loss of heterozygosity, d. All of the above

3. Epidermolysis bullosa is a classical example of
   a. Allelic heterogeneity, b. Locus heterogeneity, c. Loss of heterozygosity, d. None of the above

4. The basic step in any molecular biology experiment is a
   a. Polymerase chain reaction, b. DNA sequencing, c. Genotyping, d. Hybridization

5. Polymerase Chain reaction is used for
   a. Detecting polymorphisms in genes, b. Genetic analysis of complex diseases like psoriasis, c. Detection of microbes in small quantities, d. All of the above, 6. The technique used to study thousands of genes on one platform is e. Polymerase chain reaction, f. DNA sequencing, g. DNA micro-arrays, h. Southern Blotting.

7. All are true about positional cloning EXCEPT
   a. The first step is chromosomal assignment of the region containing the defective gene by a method called Linkage analysis, b. Genes are identified based on their chromosomal location, c. Prior knowledge of the gene and gene product is necessary, d. A typical example using this approach is Darier’s disease

8. All are true about linkage analysis EXCEPT
   a. The aim is to identify the chromosomal region that is transmitted with the disease phenotype and subsequently the disease is linked to the genetic locus which harbors the gene, b. Genome wide scans using several markers are used for this purpose, c. Family pedigrees are required, d. A LOD score of less than 3 suggests linkage.

9. A quantitative method to estimate HIV viral loads is based on
   a. Real Time PCR, b. Reverse Transcriptase PCR, c. DNA sequencing, d. Southern Blotting

10. DNA micro arrays are used for
    a. Genome-based diagnosis of neoplasms, b. Gene expression profiling of inflammatory skin conditions
    c. Mutational analysis of genodermatosis, d. All of the above

ANSWERS:
1-B, 2-A, 3-B, 4-A, 5-D, 6- C, 7- C, 8- D, 9- A,10- D